{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:31:58Z","timestamp":1790310718995,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15181-x","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:31:02Z","timestamp":1764329462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience"],"prefix":"10.1186","volume":"25","author":[{"given":"Onur","family":"Ba\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bediz Kurt","family":"\u0130nci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130mdat","family":"Ero\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa Can","family":"Efil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seher","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar Kubilay","family":"Tolunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha Koray","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cengiz","family":"Kara\u00e7in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali Nahit","family":"\u015eendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna \u00d6m\u00fcr \u00c7akmak","family":"\u00d6ks\u00fczo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"1","key":"15181_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01510-6","volume":"24","author":"AC Watt","year":"2022","unstructured":"Watt AC, Goel S. Cellular mechanisms underlying response and resistance to CDK4\/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Res. 2022;24(1):17.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"15181_CR2","first-page":"942","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Hart L, et al. Overall Survival Ribociclib Plus Letrozole Adv Breast Cancer. 2022;386(10):942\u201350.","journal-title":"Overall Survival Ribociclib Plus Letrozole Adv Breast Cancer"},{"issue":"6","key":"15181_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514\u201324.","journal-title":"N Engl J Med"},{"issue":"9","key":"15181_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101473","volume":"7","author":"M Riveiro-Barciela","year":"2025","unstructured":"Riveiro-Barciela M, De Martin E. Navigating liver toxicity in the age of novel oncological agents. JHEP Rep. 2025;7(9):101473.","journal-title":"JHEP Rep"},{"issue":"15suppl","key":"15181_CR5","doi-asserted-by":"publisher","first-page":"e13037","DOI":"10.1200\/JCO.2021.39.15_suppl.e13037","volume":"39","author":"N Jahan","year":"2021","unstructured":"Jahan N, Wongsaengsak S, Rehman S, Adhikari N, Tijani LA, Raghunath A. Relative risk of hepatotoxicity associated with cyclin-dependent kinase inhibitors (CDK4\/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials. J Clin Oncol. 2021;39(15suppl):e13037\u2013e.","journal-title":"J Clin Oncol"},{"key":"15181_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104010","volume":"79","author":"F Scirocchi","year":"2022","unstructured":"Scirocchi F, Scagnoli S, Botticelli A, Di Filippo A, Napoletano C, Zizzari IG, et al. Immune effects of CDK4\/6 inhibitors in patients with HR(+)\/HER2(-) metastatic breast cancer: relief from immunosuppression is associated with clinical response. EBioMedicine. 2022;79:104010.","journal-title":"EBioMedicine"},{"key":"15181_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jare.2024.03.019","volume":"62","author":"P-J Chen","year":"2024","unstructured":"Chen P-J, Chen S-H, Chen Y-L, Wang Y-H, Lin C-Y, Chen C-H, et al. Ribociclib leverages phosphodiesterase 4 inhibition in the treatment of neutrophilic inflammation and acute respiratory distress syndrome. J Adv Res. 2024;62:229\u201343.","journal-title":"J Adv Res"},{"issue":"7","key":"15181_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101098","volume":"6","author":"L Meunier","year":"2024","unstructured":"Meunier L, De Martin E, Delire B, Jacot W, Guiu S, Zahhaf A, et al. CDK4\/6 inhibitor-induced liver injury: clinical phenotypes and role of corticosteroid treatment. JHEP Reports. 2024;6(7):101098.","journal-title":"JHEP Reports"},{"key":"15181_CR9","doi-asserted-by":"crossref","unstructured":"Rugo HS, Lu YS, Tarantino P, Brezden-Masley C, Mouabbi JA, Gombos A et al. 351P Real-world (RW) analysis of Alanine aminotransferase (ALT)\/aspartate aminotransferase (AST) elevation in patients (pts) with metastatic breast cancer (MBC) treated with ribociclib (RIB). ESMO Open. 2025;10.","DOI":"10.1016\/j.esmoop.2025.104922"},{"key":"15181_CR10","doi-asserted-by":"crossref","unstructured":"Zurcher J-P, Goujon M, Cottu PH, Desmoulins I, Teixeira L, Mansi L et al. Feasibility of treatment with another CDK4\/6 inhibitor after severe ribociclib liver toxicity. 2023;41(16_suppl):e13067\u2013e.","DOI":"10.1200\/JCO.2023.41.16_suppl.e13067"},{"issue":"5","key":"15181_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1177\/10781552231154009","volume":"29","author":"MM Er","year":"2023","unstructured":"Er MM, Araz M, Hendem E, Ery\u0131lmaz MK, Arta\u00e7 M. Ribociclib-induced hepatotoxicity. J Oncol Pharm Pract. 2023;29(5):1275\u20137.","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"15181_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1177\/10781552231208390","volume":"30","author":"S Sozer Karadagli","year":"2024","unstructured":"Sozer Karadagli S, Gursoy P. Liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer. J Oncol Pharm Pract. 2024;30(2):404\u20137.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"15181_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59040696","volume":"59","author":"I-M Stanciu","year":"2023","unstructured":"Stanciu I-M, Pirlog CF, Anghel A-W, Parosanu AI, Olaru CM, Orlov-Slavu C, et al. Does the rechallenge with another CDK 4\/6 inhibitor in breast cancer work? A case report and literature review. Medicina (Kaunas). 2023;59(4):696.","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"15181_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/tbj.13532","volume":"26","author":"L Meynard","year":"2020","unstructured":"Meynard L, Grellety T. CDK 4\/6 inhibitor successful rechallenge after limiting hepatic toxicity. Breast J. 2020;26(2):255\u20137.","journal-title":"Breast J"},{"key":"15181_CR15","doi-asserted-by":"publisher","first-page":"121074","DOI":"10.1016\/j.lfs.2022.121074","volume":"310","author":"AG Mukherjee","year":"2022","unstructured":"Mukherjee AG, Wanjari UR, Nagarajan D, K K V VA. Letrozole: Pharmacology, toxicity and potential therapeutic effects. Life Sci. 2022;310:121074.","journal-title":"Life Sci"},{"issue":"1","key":"15181_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506442","volume":"13","author":"A Schlotman","year":"2020","unstructured":"Schlotman A, Stater A, Schuler K, Heideman J, Abramson V. Grade 3 hepatotoxicity following Fulvestrant, Palbociclib, and erdafitinib therapy in a patient with ER-positive\/PR-negative\/HER2-negative metastatic breast cancer: a case report. Case Rep Oncol. 2020;13(1):304\u20138.","journal-title":"Case Rep Oncol"},{"key":"15181_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256783","volume":"13","author":"S Schaeffer","year":"2023","unstructured":"Schaeffer S, Lutz C, Dobbie M, Terracciano LM, Matter M, Vosbeck J, et al. Ribociclib-induced liver injury: a case report. Front Oncol. 2023;13:1256783.","journal-title":"Front Oncol"},{"issue":"1","key":"15181_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/10781552211027931","volume":"28","author":"A Topcu","year":"2022","unstructured":"Topcu A, Yasin AI, Shbair AT, Besiroglu M, Simsek M, Sucuoglu Z, et al. A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer. J Oncol Pharm Pract. 2022;28(1):242\u20136.","journal-title":"J Oncol Pharm Pract"},{"key":"15181_CR19","doi-asserted-by":"crossref","unstructured":"Jacobs F, Gaudio M, Andreottola C, Borroni R, Benvenuti C, Saltalamacchia G et al. Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4\/6 inhibitors and endocrine therapy. Oncologist. 2025;30(6).","DOI":"10.1093\/oncolo\/oyaf123"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15181-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:02:53Z","timestamp":1764374573000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15181-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15181"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15181-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The need for informed consent was waived by the local Ethics Committee of Hacettepe University due to the retrospective and anonymized nature of the data.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1831"}}